Gary Nabel - AMP

It has been said that all boats rise with the tide. That’s the analogy that comes to mind when thinking about the potential of the Accelerating Medicines Partnership (AMP). By bringing together stakeholders from the National Institutes of Health (NIH), biopharmaceutical companies and several non-profit organizations, AMP is a great opportunity for all of us to join together and develop a broad-based understanding about some of the chronic conditions facing patients today. Sanofi is excited to be participating in two of the AMP focus areas: type 2 diabetes and rheumatoid arthritis/lupus. It may seem counterintuitive for 10 biopharmaceutical companies who usually are in competition to join forces for an effort such as AMP. But one of the major barriers we all have encountered in pursuit of developing better treatments – or even cures – for diabetes, lupus and rheumatoid arthritis is that very little is understood about these conditions. The puzzle is too big for any one organization to solve. By joining forces in this public-private partnership, the AMP will combine the resources, brainpower and knowledge necessary to start the process of understanding these conditions and how to treat them. Only then will we as a healthcare community reach the point where innovative new medicines are a realistic possibility. Scientific advancements rely on experimentation – testing, seeing results and learning from them. In large part, the AMP is an experiment in and of itself. Whether...
Source: PHRMA - Category: Pharmaceuticals Authors: Source Type: news